1-(3'-Methoxy-[1,1'-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)urea

ID: ALA3771200

Chembl Id: CHEMBL3771200

PubChem CID: 118064397

Max Phase: Preclinical

Molecular Formula: C30H31N3O5

Molecular Weight: 513.59

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cccc(-c2cccc(NC(=O)Nc3cc4ccc(OC5CCN(C)CC5)c(C)c4oc3=O)c2)c1

Standard InChI:  InChI=1S/C30H31N3O5/c1-19-27(37-24-12-14-33(2)15-13-24)11-10-22-18-26(29(34)38-28(19)22)32-30(35)31-23-8-4-6-20(16-23)21-7-5-9-25(17-21)36-3/h4-11,16-18,24H,12-15H2,1-3H3,(H2,31,32,35)

Standard InChI Key:  FIQOIHVQOBHRSE-UHFFFAOYSA-N

Associated Targets(Human)

HSP90AA1 Tchem Heat shock protein HSP90 (3606 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RAF1 Tclin B-raf/RAF proto-oncogene serine/threonine-protein kinase (20 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
UMSCC22B (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 513.59Molecular Weight (Monoisotopic): 513.2264AlogP: 5.89#Rotatable Bonds: 6
Polar Surface Area: 93.04Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.82CX Basic pKa: 8.54CX LogP: 4.50CX LogD: 3.33
Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.31Np Likeness Score: -0.70

References

1. Hall JA, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BS..  (2016)  Novobiocin Analogues That Inhibit the MAPK Pathway.,  59  (3): [PMID:26745854] [10.1021/acs.jmedchem.5b01354]
2. Amatya E, Blagg BSJ..  (2023)  Recent advances toward the development of Hsp90 C-terminal inhibitors.,  80  [PMID:36549397] [10.1016/j.bmcl.2022.129111]

Source